Your shopping cart is empty!
Ships within | Stock | Price | Qty | Total |
Please click "REQUEST A QUOTE" button if there is no stock, or you need other sizes or custom synthesis.
Catalog: | HY-10367 |
Brand: | MCE |
CAS: | 267243-28-7 |
MDL | MFCD09837878 |
---|---|
Molecular Weight | 485.94 |
Molecular Formula | C24H25ClFN5O3 |
SMILES | O=C(NC1=C(C=C2C(C(NC3=CC=C(C(Cl)=C3)F)=NC=N2)=C1)OCCCN4CCOCC4)C=C |
EGFR 7.4 nM (IC 50 ) |
ErbB2 9 nM (IC 50 ) |
Canertinib significantly inhibits growth of cultured melanoma cells, RaH3 and RaH5, in a dose-dependent manner. IC
50
is approximately 0.8 μM and by 5μM both cell lines are completely growth-arrested within 72 h of treatment. Incubation of exponentially growing RaH3 and RaH5 with 1 μM canertinib accumulated the cells in the G1-phase of the cell cycle within 24 h of treatment without induction of apoptosis. 1 μM canertinib inhibits ErbB1-3 receptor phosphorylation with a concomitant decrease of Akt-, Erk1/2- and Stat3 activity in both cell lines
[2]
.
Canertinib also is a potent activator of exosome secretion
[3]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Canertinib shows superior in vivo antitumor activity, giving growth delays in A431 xenografts exceeding 50 days following oral administration [1] . The growth of human malignant melanoma xenografts, RaH3 and RaH5, in nude mice is significantly inhibited by i.p. injections of 40 mg/kg/day canertinib (Fig. 4). The anti-proliferative effect on melanoma xenografts is visible already within 4 days of treatment and further increased throughout the treatment period as observed through the differences in tumor volumes, reaching statistical significance within 18 days of treatment [2] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
NCT Number | Sponsor | Condition | Start Date | Phase |
---|---|---|---|---|
NCT00174356 | Pfizer |
Carcinoma, Non-Small Cell Lung
|
December 2002 | Phase 1 |
NCT00051051 | Pfizer |
Breast Neoplasms
|
December 2002 | Phase 2 |
NCT00050830 | Pfizer |
Lung Neoplasms
|
January 2003 | Phase 2 |
Solid
Room temperature in continental US; may vary elsewhere.
Powder | -20°C | 3 years |
---|---|---|
4°C | 2 years | |
In solvent | -80°C | 6 months |
-20°C | 1 month |
Ethanol : 12.5 mg/mL ( 25.72 mM ; Need ultrasonic)
DMSO : 4.9 mg/mL ( 10.08 mM ; Need warming)
Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
---|
1 mM | 2.0579 mL | 10.2893 mL | 20.5787 mL |
5 mM | 0.4116 mL | 2.0579 mL | 4.1157 mL |
10 mM | 0.2058 mL | 1.0289 mL | 2.0579 mL |
Arctom is a premier supply platform offering over 600K unique items of Building Blocks, Bioactive Molecules, Natural Products, ADC PEG Linkers, Antibodies, and other Research Chemicals for global pharmaceutical, biotech, university, and industrial customers. We accelerate your research by providing better and faster purchasing experience & services.